TAS-102 Prolongs Survival in Metastatic Gastric, GEJ Adenocarcinoma

TAS-102 improved overall survival, compared with placebo, in patients with metastatic gastric or gastroesophageal junction (GEJ) cancer.

Source: CancerNetwork - October 15, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news